13.60
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $13.60, with a volume of 723.62K.
It is up +0.37% in the last 24 hours and up +5.92% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$13.55
Open:
$13.55
24h Volume:
723.62K
Relative Volume:
0.29
Market Cap:
$11.32B
Revenue:
$3.97B
Net Income/Loss:
$644.90M
P/E Ratio:
17.45
EPS:
0.7794
Net Cash Flow:
$90.19M
1W Performance:
-0.07%
1M Performance:
+5.92%
6M Performance:
-2.23%
1Y Performance:
-4.76%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.60 | 11.28B | 3.97B | 644.90M | 90.19M | 0.7794 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Downgrade | Goldman | Neutral → Sell |
| Jun-05-25 | Upgrade | HSBC Securities | Hold → Buy |
| Dec-19-24 | Downgrade | Nomura | Buy → Neutral |
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Dr. Reddy's Laboratories Ltd ADR (RDY-N) Stock Price and News - The Globe and Mail
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations - Investing.com UK
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Sahm
Dr. Reddy's Laboratories Ltd stock (INE089A01023): earnings miss and dual-market focus draw attentio - AD HOC NEWS
Dr. Reddy's Laboratories stock: Earnings miss shapes outlook - AD HOC NEWS
Dr. Reddy’s Labs ADR earnings missed by $0.05, revenue fell short of estimates - Investing.com India
Dr. Reddy's Earnings: Lenalidomide's Slide Digs Into Numbers, but Base Business Remains Solid - Morningstar
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast - Investing.com
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast By Investing.com - Investing.com Australia
Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS
Dr. Reddy’s (NYSE: RDY) approves new ESOP and ADR stock option grants - Stock Titan
Dr. Reddy's Grants Employee Stock Options, Raising Dilution Concerns - Whalesbook
Dr. Reddy’s Laboratories grants over 1.19 million stock options to employees - Business Upturn
RDY Stock Price, Quote & Chart | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Laboratories Ltd. Sponsored ADR Trade Ideas — LS:659157 - TradingView
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada - ChartMill
Earnings BeforeStock ScreenerSnapshot - Finviz
Dr. Reddy's on Pace for Largest Percent Increase Since June 2025 — Data Talk - Morningstar
Dr. Reddy's Labs (ADR) stock (US2565981035): Why Google Discover changes matter more now - AD HOC NEWS
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - MSN
Dr Reddy’s (NYSE: RDY) Europe head reports 8,450 ADR-backed shares - Stock Titan
Dr. Reddy’s (NYSE: RDY) North America CEO reports 47,325 ADR shares - Stock Titan
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 3,675 Equity Shares Under Employee Stock Option Plan - scanx.trade
Employee stock options add 3,675 Dr. Reddy’s (NYSE: RDY) shares - Stock Titan
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Benzinga
Dr. Reddy's Laboratories Ltd Stock Faces Analyst Downgrade Despite Strong Valuation—What European - AD HOC NEWS
Sapient Quality Select ETF Holdings - Quiver Quantitative
Dr. Reddy’s Allots New ESOP Shares, Slightly Increases Equity Capital - TipRanks
Dr. Reddy’s (NYSE: RDY) allots 10,275 ESOP shares to employees - Stock Titan
Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement - scanx.trade
Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme - scanx.trade
Dr. Reddy’s Laboratories issues 10,275 equity shares under stock options scheme - Business Upturn
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
Mercurity Fintech Holding Inc ADR share price - Mint
Mitsubishi UFJ Financial Group Inc ADR share price - Mint
3 Generic Drug Stocks to Watch Despite Industry Headwinds - The Globe and Mail
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy - ChartMill
Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action - scanx.trade
Dr. Reddy’s Stock Pops on US Launch Momentum: Buy the Breakout? - AD HOC NEWS
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes - scanx.trade
Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital - TipRanks
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test - ChartMill
US-India Trade Deal: Indian ADRs Jump Up To 6.75%; Sensex & Nifty Set For Rally - samco.in
Dr. Reddy’s Labs ADR earnings beat by $14.36, revenue topped estimates - Investing.com Australia
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):